Treatment of posttraumatic stress disorder with phenytoin: An open-label pilot study

J. Douglas Bremner, Tanya Mletzko, Silke Welter, Sajid Siddiq, Lai Reed, Chanda Williams, Christine M. Heim, Charles Nemeroff

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Phenytoin is an anticonvulsant used in the treatment of epilepsy. Its mechanism of action is incompletely understood but most likely involves modulation of glutamatergic transmission. The neurobiology of posttraumatic stress disorder (PTSD) has been hypothesized to involve, at least in part, alterations in glutamatergic transmission in the hippocampus and possibly other brain regions. The purpose of this study was to assess the effects of phenytoin on symptoms of PTSD. Method: Phenytoin was administered in an open-label fashion for 3 months to 9 adult male and female patients with DSM-IV PTSD related to a variety of traumas including childhood abuse, combat, and car accidents. Dosage was adjusted to maintain the therapeutic blood levels used in the treatment of epilepsy. Subjects were assessed before, during, and after treatment for PTSD with standardized dimensional measures of disease severity including the Clinician Administered PTSD Scale (CAPS), the Hamilton Rating Scale for Depression (HAM-D), and the Hamilton Rating Scale for Anxiety (HAM-A). Data were collected from November 2001 through June 2003. Results: Phenytoin treatment resulted in a significant decrease in PTSD symptoms as measured with the CAPS (mean score = 65 pretreatment vs. 38 posttreatment) with reductions in each of the symptom clusters of intrusions, avoidance, and hyperarousal (p < .05). There were no significant decreases in symptoms of depression severity as measured with the HAM-D or anxiety severity as measured with the HAM-A. Conclusions: These findings suggest that phenytoin may be efficacious in the treatment of PTSD, possibly mediated through its antiglutamatergic effects. Randomized, controlled, doubleblind clinical trials are indicated to further evaluate this medication in the treatment of PTSD.

Original languageEnglish
Pages (from-to)1559-1564
Number of pages6
JournalJournal of Clinical Psychiatry
Volume65
Issue number11
DOIs
StatePublished - Nov 1 2004
Externally publishedYes

Fingerprint

Phenytoin
Post-Traumatic Stress Disorders
Therapeutics
Epilepsy
Anxiety
Depression
Neurobiology
Diagnostic and Statistical Manual of Mental Disorders
Anticonvulsants
Accidents
Hippocampus
Randomized Controlled Trials
Wounds and Injuries
Brain

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Treatment of posttraumatic stress disorder with phenytoin : An open-label pilot study. / Bremner, J. Douglas; Mletzko, Tanya; Welter, Silke; Siddiq, Sajid; Reed, Lai; Williams, Chanda; Heim, Christine M.; Nemeroff, Charles.

In: Journal of Clinical Psychiatry, Vol. 65, No. 11, 01.11.2004, p. 1559-1564.

Research output: Contribution to journalArticle

Bremner, JD, Mletzko, T, Welter, S, Siddiq, S, Reed, L, Williams, C, Heim, CM & Nemeroff, C 2004, 'Treatment of posttraumatic stress disorder with phenytoin: An open-label pilot study', Journal of Clinical Psychiatry, vol. 65, no. 11, pp. 1559-1564. https://doi.org/10.4088/JCP.v65n1120
Bremner JD, Mletzko T, Welter S, Siddiq S, Reed L, Williams C et al. Treatment of posttraumatic stress disorder with phenytoin: An open-label pilot study. Journal of Clinical Psychiatry. 2004 Nov 1;65(11):1559-1564. https://doi.org/10.4088/JCP.v65n1120
Bremner, J. Douglas ; Mletzko, Tanya ; Welter, Silke ; Siddiq, Sajid ; Reed, Lai ; Williams, Chanda ; Heim, Christine M. ; Nemeroff, Charles. / Treatment of posttraumatic stress disorder with phenytoin : An open-label pilot study. In: Journal of Clinical Psychiatry. 2004 ; Vol. 65, No. 11. pp. 1559-1564.
@article{da18abf6af3a434aa7557f480dd0ac87,
title = "Treatment of posttraumatic stress disorder with phenytoin: An open-label pilot study",
abstract = "Background: Phenytoin is an anticonvulsant used in the treatment of epilepsy. Its mechanism of action is incompletely understood but most likely involves modulation of glutamatergic transmission. The neurobiology of posttraumatic stress disorder (PTSD) has been hypothesized to involve, at least in part, alterations in glutamatergic transmission in the hippocampus and possibly other brain regions. The purpose of this study was to assess the effects of phenytoin on symptoms of PTSD. Method: Phenytoin was administered in an open-label fashion for 3 months to 9 adult male and female patients with DSM-IV PTSD related to a variety of traumas including childhood abuse, combat, and car accidents. Dosage was adjusted to maintain the therapeutic blood levels used in the treatment of epilepsy. Subjects were assessed before, during, and after treatment for PTSD with standardized dimensional measures of disease severity including the Clinician Administered PTSD Scale (CAPS), the Hamilton Rating Scale for Depression (HAM-D), and the Hamilton Rating Scale for Anxiety (HAM-A). Data were collected from November 2001 through June 2003. Results: Phenytoin treatment resulted in a significant decrease in PTSD symptoms as measured with the CAPS (mean score = 65 pretreatment vs. 38 posttreatment) with reductions in each of the symptom clusters of intrusions, avoidance, and hyperarousal (p < .05). There were no significant decreases in symptoms of depression severity as measured with the HAM-D or anxiety severity as measured with the HAM-A. Conclusions: These findings suggest that phenytoin may be efficacious in the treatment of PTSD, possibly mediated through its antiglutamatergic effects. Randomized, controlled, doubleblind clinical trials are indicated to further evaluate this medication in the treatment of PTSD.",
author = "Bremner, {J. Douglas} and Tanya Mletzko and Silke Welter and Sajid Siddiq and Lai Reed and Chanda Williams and Heim, {Christine M.} and Charles Nemeroff",
year = "2004",
month = "11",
day = "1",
doi = "10.4088/JCP.v65n1120",
language = "English",
volume = "65",
pages = "1559--1564",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "11",

}

TY - JOUR

T1 - Treatment of posttraumatic stress disorder with phenytoin

T2 - An open-label pilot study

AU - Bremner, J. Douglas

AU - Mletzko, Tanya

AU - Welter, Silke

AU - Siddiq, Sajid

AU - Reed, Lai

AU - Williams, Chanda

AU - Heim, Christine M.

AU - Nemeroff, Charles

PY - 2004/11/1

Y1 - 2004/11/1

N2 - Background: Phenytoin is an anticonvulsant used in the treatment of epilepsy. Its mechanism of action is incompletely understood but most likely involves modulation of glutamatergic transmission. The neurobiology of posttraumatic stress disorder (PTSD) has been hypothesized to involve, at least in part, alterations in glutamatergic transmission in the hippocampus and possibly other brain regions. The purpose of this study was to assess the effects of phenytoin on symptoms of PTSD. Method: Phenytoin was administered in an open-label fashion for 3 months to 9 adult male and female patients with DSM-IV PTSD related to a variety of traumas including childhood abuse, combat, and car accidents. Dosage was adjusted to maintain the therapeutic blood levels used in the treatment of epilepsy. Subjects were assessed before, during, and after treatment for PTSD with standardized dimensional measures of disease severity including the Clinician Administered PTSD Scale (CAPS), the Hamilton Rating Scale for Depression (HAM-D), and the Hamilton Rating Scale for Anxiety (HAM-A). Data were collected from November 2001 through June 2003. Results: Phenytoin treatment resulted in a significant decrease in PTSD symptoms as measured with the CAPS (mean score = 65 pretreatment vs. 38 posttreatment) with reductions in each of the symptom clusters of intrusions, avoidance, and hyperarousal (p < .05). There were no significant decreases in symptoms of depression severity as measured with the HAM-D or anxiety severity as measured with the HAM-A. Conclusions: These findings suggest that phenytoin may be efficacious in the treatment of PTSD, possibly mediated through its antiglutamatergic effects. Randomized, controlled, doubleblind clinical trials are indicated to further evaluate this medication in the treatment of PTSD.

AB - Background: Phenytoin is an anticonvulsant used in the treatment of epilepsy. Its mechanism of action is incompletely understood but most likely involves modulation of glutamatergic transmission. The neurobiology of posttraumatic stress disorder (PTSD) has been hypothesized to involve, at least in part, alterations in glutamatergic transmission in the hippocampus and possibly other brain regions. The purpose of this study was to assess the effects of phenytoin on symptoms of PTSD. Method: Phenytoin was administered in an open-label fashion for 3 months to 9 adult male and female patients with DSM-IV PTSD related to a variety of traumas including childhood abuse, combat, and car accidents. Dosage was adjusted to maintain the therapeutic blood levels used in the treatment of epilepsy. Subjects were assessed before, during, and after treatment for PTSD with standardized dimensional measures of disease severity including the Clinician Administered PTSD Scale (CAPS), the Hamilton Rating Scale for Depression (HAM-D), and the Hamilton Rating Scale for Anxiety (HAM-A). Data were collected from November 2001 through June 2003. Results: Phenytoin treatment resulted in a significant decrease in PTSD symptoms as measured with the CAPS (mean score = 65 pretreatment vs. 38 posttreatment) with reductions in each of the symptom clusters of intrusions, avoidance, and hyperarousal (p < .05). There were no significant decreases in symptoms of depression severity as measured with the HAM-D or anxiety severity as measured with the HAM-A. Conclusions: These findings suggest that phenytoin may be efficacious in the treatment of PTSD, possibly mediated through its antiglutamatergic effects. Randomized, controlled, doubleblind clinical trials are indicated to further evaluate this medication in the treatment of PTSD.

UR - http://www.scopus.com/inward/record.url?scp=16544376938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544376938&partnerID=8YFLogxK

U2 - 10.4088/JCP.v65n1120

DO - 10.4088/JCP.v65n1120

M3 - Article

C2 - 15554773

AN - SCOPUS:16544376938

VL - 65

SP - 1559

EP - 1564

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 11

ER -